Neither type of diabetes is universally “worse,” but type 1 diabetes carries a greater reduction in life expectancy and demands more intensive daily management, while type 2 diabetes affects far more people and drives the majority of diabetes-related deaths worldwide simply due to its scale. The answer depends on what you mean by “worse”: daily burden, long-term complications, financial cost, or the possibility of improvement.
How Each Type Affects the Body
Type 1 and type 2 diabetes both result in high blood sugar, but they get there differently. In type 1, the immune system destroys the cells in the pancreas that produce insulin. Without insulin, your body cannot move sugar from the bloodstream into cells for energy. This process typically begins in childhood or adolescence, and once those cells are gone, they don’t come back. People with type 1 diabetes need external insulin every day for the rest of their lives.
Type 2 diabetes starts with insulin resistance. Your cells stop responding efficiently to insulin, so the pancreas has to produce more and more to keep up. Over years, the pancreas can’t maintain that pace, and blood sugar rises. Type 2 accounts for roughly 90% of all diabetes cases and affects about 8.5% of the adult population globally, compared to about 1% for type 1. It typically develops in adulthood, though rising obesity rates have pushed diagnoses into younger age groups.
What makes both types tricky is that they can start to look alike over time. People with type 2 can eventually experience pancreatic failure similar to type 1. And people with type 1 often develop insulin resistance in their liver, muscles, and fat tissue as the disease progresses.
Life Expectancy: Type 1 Takes a Larger Toll
If you’re comparing the raw impact on lifespan, type 1 diabetes is associated with a greater reduction. A meta-analysis published in Frontiers in Endocrinology found that men with type 1 diabetes lost an average of 11.3 years of life expectancy, and women lost about 10.9 years, compared to people without diabetes. For type 2, the numbers were 7.0 years for men and 6.2 years for women.
The age at which type 2 diabetes is diagnosed matters enormously, though. Research published in The Lancet Diabetes & Endocrinology found that using U.S. death rates, a person diagnosed with type 2 at age 30 died on average 14 years earlier than someone without diabetes. Diagnosed at 40, that gap shrank to 10 years. At 50, it was 6 years. Every decade of earlier diagnosis cost roughly 3 to 4 additional years of life. So a young person diagnosed with type 2 can face a life expectancy reduction that rivals or exceeds type 1.
Complications Both Types Share
High blood sugar damages blood vessels over time, and both types of diabetes lead to the same set of serious complications: kidney disease, eye damage, nerve damage, and cardiovascular disease. The rates differ somewhat between the two types, but neither gets a pass.
Kidney disease shows up in 15 to 40% of people with type 1 diabetes, compared to 5 to 20% of those with type 2. Early-stage kidney damage (microalbuminuria) develops in about 12.6% of type 1 patients over roughly seven years, while type 2 patients accumulate it at about 2% per year, reaching around 25% within a decade of diagnosis. Diabetic eye disease (retinopathy) affects roughly 10 to 21% of people with diabetes overall, with rates varying by population and how long someone has had the disease.
Heart disease and stroke are the leading causes of death for both types. Type 2 diabetes patients tend to be older and more likely to already have high blood pressure, high cholesterol, and excess weight, which compounds the cardiovascular risk. But type 1 patients face disproportionately high heart disease rates for their age, precisely because the disease starts so early.
Acute Emergencies: Different Dangers
Each type has its own signature emergency. Type 1 diabetes is closely associated with diabetic ketoacidosis (DKA), a condition where the body, starved of insulin, starts breaking down fat so aggressively that the blood becomes dangerously acidic. DKA can develop in hours and is fatal without treatment, though in-hospital mortality is generally under 2 to 3%.
Type 2 diabetes is more associated with a condition called hyperosmolar hyperglycemic state (HHS), where blood sugar climbs to extreme levels and the body becomes severely dehydrated. HHS is less common than DKA but far more deadly. Retrospective studies estimate HHS mortality at around 5% in hospital settings, with some older case series putting it closer to 20%. When DKA and HHS occur together, which can happen, mortality rises to about 8%.
Daily Management and Hypoglycemia
The day-to-day burden of type 1 diabetes is heavier. You must monitor blood sugar continuously, count carbohydrates, and administer insulin through injections or a pump for every meal and throughout the day. There is no oral medication alternative. Missing a dose or miscalculating can send blood sugar dangerously high or low within hours.
Hypoglycemia (blood sugar dropping too low) is a constant concern for people on insulin, and it’s significantly more common in type 1. A systematic review found that hypoglycemia rates in type 1 ranged from 14.5 to 42,890 episodes per 1,000 person-years, compared to 0.072 to 16,360 per 1,000 person-years in type 2. That enormous range reflects differences in how studies measured episodes, but the pattern is consistent: type 1 carries a substantially higher risk. Severe hypoglycemia can cause seizures, loss of consciousness, and death.
Type 2 diabetes management varies widely. Some people manage with diet and exercise alone. Others take oral medications, and some eventually need insulin. The daily routine is generally less intensive, especially in the earlier stages, but it still requires consistent attention to diet, activity, and medication.
Can Either Type Go Into Remission?
This is one area where type 2 has a clear advantage. Type 2 diabetes can go into remission, defined by the American Diabetes Association as maintaining blood sugar levels below the diagnostic threshold for at least three months without any diabetes medication. Significant weight loss, particularly through dietary changes or bariatric surgery, is the most reliable path to remission. Not everyone achieves it, and it becomes less likely the longer someone has had the disease, but it is possible.
Type 1 diabetes has no remission. Because the immune system has destroyed the insulin-producing cells, the condition is permanent. Some people experience a brief “honeymoon phase” after diagnosis where the remaining cells still produce small amounts of insulin, but this fades. Insulin therapy is lifelong.
Financial Cost
Type 1 diabetes is more expensive. In 2018, average total healthcare costs for a person with type 1 were $25,652 per year, compared to $22,408 for type 2 and $14,221 for someone without diabetes. Out-of-pocket costs followed the same pattern: $2,037 for type 1 versus $1,543 for type 2. Medication costs made up the largest share of out-of-pocket spending for both types, accounting for over half of what patients paid directly. The cost of insulin, continuous glucose monitors, and pump supplies drives much of the difference for type 1.
So Which Is Actually Worse?
Type 1 diabetes is harder to live with on a daily basis, more expensive, more prone to dangerous blood sugar swings, and associated with a larger reduction in life expectancy. It strikes earlier in life, cannot go into remission, and requires constant, active management with no breaks.
Type 2 diabetes, however, is not the “mild” version it’s sometimes portrayed as. It causes the same devastating complications, and when diagnosed young, it can shorten life just as dramatically as type 1. Its sheer prevalence means it causes far more total suffering and death worldwide. The difference is that type 2 offers more tools for management and, in some cases, a real shot at remission.
Calling one “worse” oversimplifies what are two serious, lifelong conditions. But if you’re comparing the experience of an individual patient, type 1 diabetes generally imposes a greater daily burden and a steeper long-term cost to health and lifespan, especially with current treatments.